Switch theme
Sign up to access all valuation multiples
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
2008
176
LTM Revenue $115M
LTM EBITDA -$75.2M
$359M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arcturus Therapeutics has a last 12-month revenue (LTM) of $115M and a last 12-month EBITDA of -$75.2M.
In the most recent fiscal year, Arcturus Therapeutics achieved revenue of $138M and an EBITDA of -$77.4M.
Arcturus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arcturus Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $115M | XXX | $138M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$75.2M | XXX | -$77.4M | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | -56% | XXX | XXX | XXX |
| EBIT | -$83.9M | XXX | -$95.7M | XXX | XXX | XXX |
| EBIT Margin | -73% | XXX | -69% | XXX | XXX | XXX |
| Net Profit | -$71.5M | XXX | -$80.9M | XXX | XXX | XXX |
| Net Margin | -62% | XXX | -58% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Arcturus Therapeutics's stock price is $19.
Arcturus Therapeutics has current market cap of $529M, and EV of $359M.
See Arcturus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $359M | $529M | XXX | XXX | XXX | XXX | $-2.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Arcturus Therapeutics has market cap of $529M and EV of $359M.
Arcturus Therapeutics's trades at 2.6x EV/Revenue multiple, and -4.6x EV/EBITDA.
Equity research analysts estimate Arcturus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcturus Therapeutics has a P/E ratio of -7.4x.
See valuation multiples for Arcturus Therapeutics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $529M | XXX | $529M | XXX | XXX | XXX |
| EV (current) | $359M | XXX | $359M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | -4.8x | XXX | -4.6x | XXX | XXX | XXX |
| EV/EBIT | -4.3x | XXX | -3.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.4x | XXX | -6.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArcturus Therapeutics's last 12 month revenue growth is -10%
Arcturus Therapeutics's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.3M for the same period.
Arcturus Therapeutics's rule of 40 is -25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcturus Therapeutics's rule of X is -91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arcturus Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | -11% | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | -56% | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -25% | XXX | -66% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -91% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 141% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 169% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcturus Therapeutics acquired XXX companies to date.
Last acquisition by Arcturus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Arcturus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Arcturus Therapeutics founded? | Arcturus Therapeutics was founded in 2008. |
| Where is Arcturus Therapeutics headquartered? | Arcturus Therapeutics is headquartered in United States of America. |
| How many employees does Arcturus Therapeutics have? | As of today, Arcturus Therapeutics has 176 employees. |
| Who is the CEO of Arcturus Therapeutics? | Arcturus Therapeutics's CEO is Mr. Joseph E. Payne. |
| Is Arcturus Therapeutics publicy listed? | Yes, Arcturus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Arcturus Therapeutics? | Arcturus Therapeutics trades under ARCT ticker. |
| When did Arcturus Therapeutics go public? | Arcturus Therapeutics went public in 2013. |
| Who are competitors of Arcturus Therapeutics? | Similar companies to Arcturus Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Arcturus Therapeutics? | Arcturus Therapeutics's current market cap is $529M |
| What is the current revenue of Arcturus Therapeutics? | Arcturus Therapeutics's last 12 months revenue is $115M. |
| What is the current revenue growth of Arcturus Therapeutics? | Arcturus Therapeutics revenue growth (NTM/LTM) is -10%. |
| What is the current EV/Revenue multiple of Arcturus Therapeutics? | Current revenue multiple of Arcturus Therapeutics is 3.1x. |
| Is Arcturus Therapeutics profitable? | Yes, Arcturus Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arcturus Therapeutics? | Arcturus Therapeutics's last 12 months EBITDA is -$75.2M. |
| What is Arcturus Therapeutics's EBITDA margin? | Arcturus Therapeutics's last 12 months EBITDA margin is -66%. |
| What is the current EV/EBITDA multiple of Arcturus Therapeutics? | Current EBITDA multiple of Arcturus Therapeutics is -4.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
